Bicycle Therapeutics (BCYC) Capital Expenditures (2018 - 2026)
Bicycle Therapeutics' (BCYC) quarterly Capital Expenditures came in at $265000.0 in Q2 2026, down 46.79% YoY from $498000.0 in Q2 2025, and down 62.83% on a QoQ basis from $713000.0 in Q1 2026.
Bicycle Therapeutics (BCYC) Capital Expenditures (2018 - 2026) Analysis & Trends
Bicycle Therapeutics (BCYC) has 9 years of Capital Expenditures data on file, last reported at $265000.0 in Q2 2026.
- Quarterly Capital Expenditures fell 46.79% year-over-year to $265000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $2.2 million (up 16.85% YoY) and the FY2025 annual result came in at $2.4 million, up 90.28% from the prior year.
- Capital Expenditures fell to $265000.0 in Q2 2026, from $713000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $9.8 million in Q2 2022 to a low of $12000.0 in Q1 2024.
- A 5-year average of $1.5 million and a median of $538000.0 in 2023 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2022 — Capital Expenditures surged 5630.41% — and 2024, when it tumbled 99.43%.
- Tracing BCYC's Capital Expenditures over 5 years: stood at $1.4 million in 2022, then slumped by 96.48% to $51000.0 in 2023, then surged by 621.57% to $368000.0 in 2024, then jumped by 55.98% to $574000.0 in 2025, then sank by 53.83% to $265000.0 in 2026.
- The last three Capital Expenditures figures came in at $265000.0 (Q2 2026), $713000.0 (Q1 2026), and $574000.0 (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Bicycle Therapeutics | 272.28 Mn | 272.28 Mn | - | 265,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 265,000.00 |
| Jun 30, 2026 | 265,000.00 |
| Mar 31, 2026 | 713,000.00 |
| Mar 31, 2026 | 713,000.00 |
| Dec 31, 2025 | 574,000.00 |
| Dec 31, 2025 | 574,000.00 |
| Sep 30, 2025 | 674,000.00 |
| Sep 30, 2025 | 674,000.00 |
| Jun 30, 2025 | 498,000.00 |
| Jun 30, 2025 | 498,000.00 |
| Mar 31, 2025 | 604,000.00 |
| Mar 31, 2025 | 604,000.00 |
| Dec 31, 2024 | 368,000.00 |
| Dec 31, 2024 | 368,000.00 |
| Sep 30, 2024 | 435,000.00 |
| Sep 30, 2024 | 435,000.00 |
| Jun 30, 2024 | 420,000.00 |
| Jun 30, 2024 | 420,000.00 |
| Mar 31, 2024 | 12,000.00 |
| Mar 31, 2024 | 12,000.00 |